^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Keytruda (pembrolizumab)

    i
    Other names: MK-3475, SCH 900475, 1374853-91-4, ORG 307488, SCH-900475, SCH900475, ORG 307488-0, MK 3475, MK3475
    Company:
    Merck (MSD)
    Drug class:
    PD1 inhibitor
    Related drugs:
    16h
    Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies (clinicaltrials.gov)
    P2, N=0, Withdrawn, NGM Biopharmaceuticals, Inc
    New P2 trial
    |
    Keytruda (pembrolizumab)
    19h
    GEN1046 Safety Trial in Patients With Malignant Solid Tumors (clinicaltrials.gov)
    P1/2, N=429, Active, not recruiting, Genmab | Trial completion date: Feb 2026 --> Aug 2026
    Trial completion date • First-in-human
    |
    Keytruda (pembrolizumab) • docetaxel • acasunlimab (GEN1046)
    20h
    LaPemERLA: Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole (clinicaltrials.gov)
    P2, N=40, Recruiting, National Cancer Centre, Singapore | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 amplification • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib) • letrozole
    20h
    Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma (clinicaltrials.gov)
    P2, N=20, Suspended, M.D. Anderson Cancer Center | Not yet recruiting --> Suspended
    Trial suspension
    |
    Keytruda (pembrolizumab) • zanzalintinib (XL092)
    1d
    NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1/2, N=29, Active, not recruiting, University of Colorado, Denver | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • NT219
    1d
    FRAPPE: Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Mayo Clinic | Trial completion date: Jul 2027 --> Jun 2028 | Trial primary completion date: Jul 2027 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Keytruda (pembrolizumab)
    1d
    SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC. (PubMed, Future Oncol)
    www.clinicaltrials.gov identifier is NCT06119581. EudraCT: 2023-503412-33-00.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • olomorasib (LY3537982)
    2d
    POCHI: Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate (clinicaltrials.gov)
    P2, N=55, Recruiting, Federation Francophone de Cancerologie Digestive | Not yet recruiting --> Recruiting
    Enrollment open • Tumor mutational burden
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • capecitabine • oxaliplatin
    2d
    ASP-1929-381: Study of the combination of the drug ASP-1929 and light illumination with the device PIT690 laser system in addition with pembrolizumab versus Standard of Care in the treatment of locoregional recurrent squamous cell carcinoma of the head and neck with no distant metastases (2025-523017-28-00)
    P2/3, N=30, Not yet recruiting, Rakuten Medical Inc.
    New P2/3 trial
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • docetaxel • 5-fluorouracil • Akalux (cetuximab sarotalocan)
    2d
    Contrasting responses to neoadjuvant immunotherapy in synchronous transverse colon cancers with discordant mismatch repair status. (PubMed, Jpn J Clin Oncol)
    Given the advanced dMMR status of the primary lesion, neoadjuvant immunotherapy with pembrolizumab was administered, resulting in marked radiologic tumor regression...This case represents a rare intra-patient demonstration of dMMR status, together with a CD8-rich tumor microenvironment, conferring considerable sensitivity to ICI therapy, and pMMR status exhibiting resistance, despite identical systemic immune exposure. Our findings suggest that MMR status may serve as a clinically relevant biomarker for response to neoadjuvant immunotherapy in CRC and highlight the importance of independent biomarker assessment for each synchronous tumor.
    Journal • Mismatch repair • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab)
    3d
    A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site. (PubMed, Eur J Cancer)
    This is the first study investigating the safety and efficacy of pembrolizumab in untreated CUP patients. Some responses were observed, but this primary endpoint was not met. We recommend screening all CUP patients for MMR/microsatellite instability (MSI). Future studies should evaluate combination therapies with pembrolizumab.
    P2 data • Journal
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
    |
    Keytruda (pembrolizumab)
    4d
    NCI-2018-00115: Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability (clinicaltrials.gov)
    P2, N=21, Active, not recruiting, Rutgers, The State University of New Jersey | Recruiting --> Active, not recruiting | N=40 --> 21 | Trial completion date: Oct 2023 --> Sep 2027
    Enrollment closed • Enrollment change • Trial completion date • Pan tumor
    |
    PD-L1 (Programmed death ligand 1) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • POLE (DNA Polymerase Epsilon) • POLD1 (DNA Polymerase Delta 1)
    |
    BRCA1 mutation • POLD1 mutation
    |
    Keytruda (pembrolizumab)